Your browser doesn't support javascript.
loading
Comparison of the recovery rate of otomycosis using betadine and clotrimazole topical treatment / Comparação da taxa de recuperação de otomicose com o uso de tratamento tópico com betadina e clotrimazol
Mofatteh, Mohammad Reza; Yazdi, Zahra Naseripour; Yousefi, Masoud; Namaei, Mohammad Hasan.
  • Mofatteh, Mohammad Reza; Birjand University of Medical Science. School of Medicine. Department of Ears. Birjand. IR
  • Yazdi, Zahra Naseripour; Birjand University of Medical Sciences. School of Medicine. Birjand. IR
  • Yousefi, Masoud; Birjand University of Medical Science. Infectious Diseases Research Center. Birjand. IR
  • Namaei, Mohammad Hasan; Birjand University of Medical Science. Infectious Diseases Research Center. Birjand. IR
Braz. j. otorhinolaryngol. (Impr.) ; 84(4): 404-409, July-Aug. 2018. tab
Article in English | LILACS | ID: biblio-951858
ABSTRACT
Abstract Introduction Otomycosis is a common diseases that can be associated with many complications including involvement of the inner ear and mortality in rare cases. Management of otomycosis can be challenging, and requires a close follow-up. Treatment options for otomycosis include local debridement, local and systemic antifungal agents and utilization of topical antiseptics. Objective This study was designed to compare the recovery rate of otomycosis using two therapeutic methods; topical betadine (Povidone-iodine) and clotrimazole. Methods In this single-blind clinical trial, 204 patients with otomycosis were selected using a non-probability convenient sampling method and were randomly assigned to two treatment groups of topical betadine and clotrimazole (102 patients in each group). Response to treatment was assessed at 4, 10 and 20 days after treatment. Data were analyzed using the independent t-test, Chi-Square and Fisher exact test in SPSS v.18 software, at a significance level of p < 0.05. Results The results showed that out of 204 patients with otomycosis, fungi type isolated included Aspergillus in 151 cases (74%), and Candida albicans in 53 patients (26%). On the fourth day after treatment, 13 patients (13.1%) in the group treated with betadine and 10 patients (9.8%) in the group treated with clotrimazole showed a good clinical response to treatment (p = 0.75). A good response to treatment was reported for 44 (43.1%) and 47 patients (46.1%) on the tenth day after the treatment (p = 0.85); and 70 (68.6%) and 68 patients (67.6%) on the twentieth day after treatment (p = 0.46) in the groups treated with betadine and clotrimazole, respectively. The response to treatment was thus not significantly different in the two groups. Conclusion In the present study the efficacy of betadine and clotrimazole was the same for the treatment of otomycosis. The result of this study supports the use of betadine as an effective antifungal in otomycosis treatment, helping to avoid the emergence of resistant organisms.
RESUMO
Resumo Introdução A otomicose é uma das doenças comuns associadas a muitas complicações, como envolvimento da orelha interna e mortalidade em casos raros. O tratamento da otomicose pode ser realmente desafiador e requer um acompanhamento rigoroso. As opções de tratamento para otomicose podem incluir desbridamento local, agentes antifúngicos locais e sistêmicos e uso de antissépticos tópicos, os medicamentos tópicos recomendados para o tratamento da otomicose. Objetivo Comparar a taxa de recuperação de otomicose utilizando dois métodos terapêuticos de betadina tópica (povidona-iodo) e clotrimazol. Método Neste ensaio clínico simples cego, 204 pacientes com otomicose foram selecionados utilizando-se método de amostragem de não probabilidade conveniente e randomizados para dois grupos de tratamento, com betadina tópica e com clotrimazol (102 pacientes em cada grupo). A resposta ao tratamento foi avaliada aos 4, 10 e 20 dias após o tratamento. Os dados foram analisados utilizando o teste t independente, qui-quadrado e teste de Fisher no software SPSS v.18, com nível de significância de p < 0,05. Resultados Os resultados mostraram que dos 204 pacientes com otomicose, os tipos de fungos isolados incluíram Aspergillus em 151 casos (74%) e Candida albicans em 53 pacientes (26%). No quarto dia após o tratamento, 13 pacientes (13,1%) no grupo tratado com betadina e 10 pacientes (9,8%) no grupo tratado com clotrimazol apresentaram boa resposta ao tratamento (p = 0,75). Uma boa resposta ao tratamento foi relatada para 44 (43,1%) e 47 pacientes (46,1%) no décimo dia após o tratamento (p = 0,85); e 70 (68,6%) e 68 pacientes (67,6%) no vigésimo dia após o tratamento (p = 0,46) no grupo tratado com betadina e clotrimazol, respectivamente. Assim, a resposta ao tratamento não foi significativamente diferente nos dois grupos. Conclusão No presente estudo, a eficácia da betadina e do clotrimazol foi a mesma no tratamento da otomicose. O resultado deste estudo apoia o uso de betadina como um antifúngico eficaz no tratamento da otomicose que pode ajudar a evitar o surgimento de organismos resistentes.
Subject(s)


Full text: Available Index: LILACS (Americas) Main subject: Povidone-Iodine / Clotrimazole / Otomycosis / Anti-Infective Agents, Local / Antifungal Agents Type of study: Controlled clinical trial / Incidence study Limits: Adult / Female / Humans / Male Language: English Journal: Braz. j. otorhinolaryngol. (Impr.) Journal subject: Otolaryngology Year: 2018 Type: Article Affiliation country: Iran Institution/Affiliation country: Birjand University of Medical Science/IR / Birjand University of Medical Sciences/IR

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Main subject: Povidone-Iodine / Clotrimazole / Otomycosis / Anti-Infective Agents, Local / Antifungal Agents Type of study: Controlled clinical trial / Incidence study Limits: Adult / Female / Humans / Male Language: English Journal: Braz. j. otorhinolaryngol. (Impr.) Journal subject: Otolaryngology Year: 2018 Type: Article Affiliation country: Iran Institution/Affiliation country: Birjand University of Medical Science/IR / Birjand University of Medical Sciences/IR